Alectinib ALK inhibitors

Description Results NMA

PFS 0.15 [0.08; 0.29] median 9.6 vs. 1.4

oral alectinib at a dose of 600 milligrams (mg) twice daily (n=-9)

vs.

chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously. (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

PFS 0.47 [0.34; 0.65] median NR vs. 11.1 mo Demonstrated

OS 0.76 [0.48; 1.20] median NR vs. NR

alectinib 600 mg orally (four 150 mg capsules) BID (n=152)

vs.

Crizotinib (n=151)

open label

Parallel groups

Sample size: 152/151

Primary endpoint: Investigator assessed PFS

FU duration: